Skip to content

US · KRYS · BIOTECHNOLOGY

Krystal Biotech, Inc. (KRYS) intrinsic value and stock valuation

$308.89as of 2026-11-21 · Mkt cap 9.6B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Krystal Biotech, Inc. DCF and intrinsic value

InvestorsCraft values KRYS with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from KRYS’s statements →

Krystal Biotech, Inc. Graham Number

Graham Number: $81.91d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Pittsburgh, PA 15203 krystalbio.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$389.1M
20162025
Net income
$204.8M
20162025
Free cash flow
$188.9M
20162025
Total equity
$1.22B+33.1% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$389.1M$290.5M$50.7M$0.00$0.00
Operating income$161.3M$65.7M-$-109.73M-$-145.2M-$-68.28M
Net income$204.8M$89.2M$10.9M-$-139.97M-$-69.57M
EPSd$6.84M$3M$393.9K-$-5.49M-$-3.13M
Operating cash flow$200.9M$123.4M-$-88.8M-$-100.57M-$-47.94M
Capital expenditure-$-11.95M-$-4.24M-$-11.8M-$-52.98M-$-68.34M
Free cash flow$188.9M$119.2M-$-100.6M-$-153.55M-$-116.27M
Total assets$1.33B$1.06B$818.4M$558.5M$626.3M
Total debt$9.34M$7.26M$8.09M$8.93M$8.02M
Net debt-$-486.96M-$-337.6M-$-350.23M-$-152.97M-$-333.22M
Total equity$1.22B$946.4M$778.6M$522.2M$593.6M
Cash and short-term investments$827.8M$597.5M$532.2M$379.2M$438.1M
Income statement
20252024202320222021
Revenue$389.1M$290.5M$50.7M$0.00$0.00
Cost of revenue$28.8M$20.1M$3.09M$0.00$0.00
Gross profit$360.4M$270.5M$47.6M$0.00$0.00
Research and development expenses$58.1M$53.6M$46.4M$42.5M$27.9M
Selling, general and administrative expenses$146.7M$113.7M$98.4M$77.7M$40.4M
Other expenses-$-5.72M$37.5M$12.5M$25M$0.00
Operating expenses$199.1M$204.8M$157.3M$145.2M$68.3M
Cost and expenses$227.8M$224.8M$160.4M$145.2M$68.3M
Interest income$28.2M$29.7M$22.6M$5.22M$200K
Interest expense$0.00$0.00$0.00$0.00$1.49M
Depreciation and amortization$6.55M$6.71M$5.91M$3.38M$1.85M
Ebitda$196M$109.9M-$-91.32M-$-116.81M-$-66.23M
Operating income$161.3M$65.7M-$-109.73M-$-145.2M-$-68.28M
Total other income/expenses, net$28.2M$29.7M$122.6M$5.22M-$-1.29M
Income before tax$189.5M$95.4M$12.9M-$-139.97M-$-69.57M
Income tax expense-$-15.36M$6.2M$1.97M$0.00$0.00
Net income$204.8M$89.2M$10.9M-$-139.97M-$-69.57M
Weighted average shares outstanding$28.9M$28.6M$27.2M$25.5M$22.2M
Weighted average diluted shares outstanding$30M$29.7M$27.8M$25.5M$22.2M
Balance sheet
20252024202320222021
Cash and short-term investments$827.8M$597.5M$532.2M$379.2M$438.1M
Net receivables$127.4M$104.8M$42M$0.00$0.00
Inventory$40.5M$26.5M$6.99M$0.00$0.00
Total current assets$1.02B$742M$587.9M$383.8M$442.3M
Property, plant and equipment, net$158M$161.5M$168.2M$169.7M$119.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$128.1M$152.1M$62M$4.62M$64.4M
Total non-current assets$309.2M$313.8M$230.5M$174.7M$184M
Total assets$1.33B$1.06B$818.4M$558.5M$626.3M
Accounts payable$3.24M$4.99M$1.85M$3.98M$8.4M
Short-term debt$1.77M$1.22M$1.47M$1.56M$1.04M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$102.9M$102M$33.1M$28.9M$25.7M
Long-term debt$7.57M$6.04M$6.62M$7.37M$6.98M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$11.3M$7.46M$6.62M$7.37M$6.98M
Capital lease obligations$9.34M$7.26M$8.09M$8.93M$8.02M
Total liabilities$114.2M$109.5M$39.7M$36.2M$32.7M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings$24.2M-$-180.67M-$-269.83M-$-280.76M-$-140.78M
Accumulated other comprehensive income (loss)$1.14M-$-190K$640K-$-730K-$-160K
Total equity$1.22B$946.4M$778.6M$522.2M$593.6M
Total investments$459.6M$404.8M$235.8M$221.9M$161.2M
Total debt$9.34M$7.26M$8.09M$8.93M$8.02M
Net debt-$-486.96M-$-337.6M-$-350.23M-$-152.97M-$-333.22M
Cash flow statement
20252024202320222021
Net income$204.8M$89.2M$10.9M-$-139.97M-$-69.57M
Depreciation and amortization$6.55M$6.71M$5.01M$4.05M$2.77M
Stock-based compensation$54.5M$49.1M$39.9M$33.2M$15.3M
Change in working capital-$-36.42M-$-14.46M-$-37.88M$2.81M$2.05M
Accounts receivable-$-22.12M-$-62.71M-$-42.04M$0.00$0.00
Inventory-$-6.29M-$-11.91M-$-4.47M$0.00$0.00
Accounts payable$830K$1.01M-$-100K-$-1.25M$710K
Net cash provided by operating activities$200.9M$123.4M-$-88.8M-$-100.57M-$-47.94M
Investments in property, plant and equipment-$-11.95M-$-4.24M-$-11.8M-$-52.98M-$-68.34M
Acquisitions, net$430K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-58.42M-$-163.44M$82.6M-$-114.08M-$-226.77M
Common stock issued$22.7M$32.4M$203.5M$36M$355.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.71M$27M$202.8M$35.4M$347.7M
Net change in cash$151.4M-$-13.46M$196.4M-$-179.35M$73M
Cash at end of period$496.3M$344.9M$358.3M$161.9M$341.3M
Operating cash flow$200.9M$123.4M-$-88.8M-$-100.57M-$-47.94M
Capital expenditure-$-11.95M-$-4.24M-$-11.8M-$-52.98M-$-68.34M
Free cash flow$188.9M$119.2M-$-100.6M-$-153.55M-$-116.27M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Krystal Biotech, Inc.

        Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

        CEO
        Krish S. Krishnan
        Employees
        295
        Beta
        0.50

        Explore

        Frequently asked questions

        What is the intrinsic value of Krystal Biotech, Inc. (KRYS)?

        Krystal Biotech, Inc. (KRYS) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is KRYS undervalued?

        KRYS trades at a price of $308.89 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.